Imatinib (400 mg/day) versus imatinib (600 mg/day) in patients with advanced GIST

Trial Profile

Imatinib (400 mg/day) versus imatinib (600 mg/day) in patients with advanced GIST

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results of a genomic analysis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top